Benign fibrocystic breast disease

Indication for Danazol

Population group: Suitable for women, only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Danazol is recommended for the treatment of benign fibrocystic breast disease. Symptomatic relief of severe pain and tenderness. Danazol should be used only in patients not responsive to other therapeutic measures or for whom such measures are inadvisable.

For this indication, competent medicine agencies globally authorize below treatments:

300 mg in 2 divided doses daily

Route of admnistration


Defined daily dose

100 - 400 mg

Dosage regimen

From 50 To 200 mg 2 time(s) per day every day

Detailed description

In benign fibrocystic breast disease, treatment should commence at a dose of 300mg daily, a course of treatment normally lasting 3 to 6 months.

Active ingredient

Danazol is a synthetic steroid derived from ethisterone an is indicated for the treatment of endometriosis and benign fibrocystic breast disease.

Read more about Danazol

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner